NYSE:CRY

CryoLife Competitors

$20.87

+0.83 (+4.14 %)

(As of 11/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$19.93

Now: $20.87▼

$20.88

50-Day Range

$16.76

MA: $18.92▼

$20.93

52-Week Range

$12.63

Now: $20.87▼

$31.77

Volume122,149 shs

Average Volume298,448 shs

Market Capitalization$810.95 million

P/E RatioN/A

Dividend YieldN/A

Beta1.37

CryoLife (NYSE:CRY) Vs. ABT, MDT, SYK, ISRG, BDX, and EW

Should you be buying CRY stock or one of its competitors? Companies in the sub-industry of "health care equipment" are considered alternatives and competitors to CryoLife, including Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton, Dickinson and (BDX), and Edwards Lifesciences (EW).

CryoLife vs. Abbott Laboratories Stock

CryoLife (NYSE:CRY) and Abbott Laboratories (NYSE:ABT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CryoLife and Abbott Laboratories, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CryoLife	0	1	4	0	2.80
Abbott Laboratories	1	4	13	0	2.67

CryoLife currently has a consensus target price of $27.25, suggesting a potential upside of 30.57%. Abbott Laboratories has a consensus target price of $115.3750, suggesting a potential upside of 5.59%. Given CryoLife's stronger consensus rating and higher probable upside, analysts plainly believe CryoLife is more favorable than Abbott Laboratories.

Earnings and Valuation

This table compares CryoLife and Abbott Laboratories' top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CryoLife	$276.22 million	2.94	$1.72 million	$0.31	67.32
Abbott Laboratories	$31.90 billion	6.07	$3.69 billion	$3.24	33.73

Abbott Laboratories has higher revenue and earnings than CryoLife. Abbott Laboratories is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CryoLife and Abbott Laboratories' net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CryoLife	-5.45%	1.86%	0.82%
Abbott Laboratories	10.50%	18.19%	8.29%

Volatility & Risk

CryoLife has a beta of 1.37, meaning that its share price is 37% more volatile than the S&P 500. Comparatively, Abbott Laboratories has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500.

Insider and Institutional Ownership

74.7% of CryoLife shares are held by institutional investors. Comparatively, 63.9% of Abbott Laboratories shares are held by institutional investors. 4.7% of CryoLife shares are held by company insiders. Comparatively, 1.7% of Abbott Laboratories shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Abbott Laboratories beats CryoLife on 9 of the 14 factors compared between the two stocks.

CryoLife vs. Medtronic Stock

Medtronic (NYSE:MDT) and CryoLife (NYSE:CRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Medtronic and CryoLife, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medtronic	1	3	20	1	2.84
CryoLife	0	1	4	0	2.80

Medtronic presently has a consensus price target of $118.1538, indicating a potential upside of 6.47%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's higher probable upside, analysts plainly believe CryoLife is more favorable than Medtronic.

Valuation & Earnings

This table compares Medtronic and CryoLife's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medtronic	$28.91 billion	5.16	$4.79 billion	$4.59	24.18
CryoLife	$276.22 million	2.94	$1.72 million	$0.31	67.32

Medtronic has higher revenue and earnings than CryoLife. Medtronic is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medtronic and CryoLife's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medtronic	15.80%	10.47%	5.80%
CryoLife	-5.45%	1.86%	0.82%

Volatility and Risk

Medtronic has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

79.9% of Medtronic shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 0.5% of Medtronic shares are owned by insiders. Comparatively, 4.7% of CryoLife shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats CryoLife on 12 of the 15 factors compared between the two stocks.

CryoLife vs. Stryker Stock

Stryker (NYSE:SYK) and CryoLife (NYSE:CRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, valuation, dividends and earnings.

Analyst Ratings

This is a breakdown of recent ratings for Stryker and CryoLife, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Stryker	2	9	15	1	2.56
CryoLife	0	1	4	0	2.80

Stryker presently has a consensus price target of $221.44, indicating a potential downside of 4.97%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher probable upside, analysts plainly believe CryoLife is more favorable than Stryker.

Valuation & Earnings

This table compares Stryker and CryoLife's gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Stryker	$14.88 billion	5.88	$2.08 billion	$8.26	28.21
CryoLife	$276.22 million	2.94	$1.72 million	$0.31	67.32

Stryker has higher revenue and earnings than CryoLife. Stryker is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Stryker and CryoLife's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Stryker	11.38%	20.53%	8.89%
CryoLife	-5.45%	1.86%	0.82%

Volatility and Risk

Stryker has a beta of 0.78, suggesting that its share price is 22% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.

Insider and Institutional Ownership

71.0% of Stryker shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 6.8% of Stryker shares are owned by insiders. Comparatively, 4.7% of CryoLife shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Stryker beats CryoLife on 11 of the 15 factors compared between the two stocks.

CryoLife vs. Intuitive Surgical Stock

Intuitive Surgical (NASDAQ:ISRG) and CryoLife (NYSE:CRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Intuitive Surgical and CryoLife's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	24.45%	12.08%	10.44%
CryoLife	-5.45%	1.86%	0.82%

Insider and Institutional Ownership

86.9% of Intuitive Surgical shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 1.6% of Intuitive Surgical shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Intuitive Surgical has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Valuation and Earnings

This table compares Intuitive Surgical and CryoLife's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$4.48 billion	18.87	$1.38 billion	$9.95	72.27
CryoLife	$276.22 million	2.94	$1.72 million	$0.31	67.32

Intuitive Surgical has higher revenue and earnings than CryoLife. CryoLife is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Intuitive Surgical and CryoLife, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	3	7	12	0	2.41
CryoLife	0	1	4	0	2.80

Intuitive Surgical presently has a consensus price target of $718.2778, indicating a potential downside of 0.11%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher possible upside, analysts plainly believe CryoLife is more favorable than Intuitive Surgical.

Summary

Intuitive Surgical beats CryoLife on 10 of the 14 factors compared between the two stocks.

CryoLife vs. Becton, Dickinson and Stock

Becton, Dickinson and (NYSE:BDX) and CryoLife (NYSE:CRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Becton, Dickinson and and CryoLife's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Becton, Dickinson and	5.11%	13.30%	5.60%
CryoLife	-5.45%	1.86%	0.82%

Insider and Institutional Ownership

74.4% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 0.1% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Becton, Dickinson and has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Valuation and Earnings

This table compares Becton, Dickinson and and CryoLife's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Becton, Dickinson and	$17.12 billion	3.87	$874 million	$10.20	22.40
CryoLife	$276.22 million	2.94	$1.72 million	$0.31	67.32

Becton, Dickinson and has higher revenue and earnings than CryoLife. Becton, Dickinson and is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Becton, Dickinson and and CryoLife, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Becton, Dickinson and	0	7	7	1	2.60
CryoLife	0	1	4	0	2.80

Becton, Dickinson and presently has a consensus price target of $280.2857, indicating a potential upside of 22.67%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher possible upside, analysts plainly believe CryoLife is more favorable than Becton, Dickinson and.

Summary

Becton, Dickinson and beats CryoLife on 10 of the 15 factors compared between the two stocks.

CryoLife vs. Edwards Lifesciences Stock

Edwards Lifesciences (NYSE:EW) and CryoLife (NYSE:CRY) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares Edwards Lifesciences and CryoLife's net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edwards Lifesciences	18.18%	29.00%	18.10%
CryoLife	-5.45%	1.86%	0.82%

Insider and Institutional Ownership

79.7% of Edwards Lifesciences shares are owned by institutional investors. Comparatively, 74.7% of CryoLife shares are owned by institutional investors. 1.5% of Edwards Lifesciences shares are owned by company insiders. Comparatively, 4.7% of CryoLife shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Volatility & Risk

Edwards Lifesciences has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500. Comparatively, CryoLife has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.

Valuation and Earnings

This table compares Edwards Lifesciences and CryoLife's gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edwards Lifesciences	$4.35 billion	12.14	$1.05 billion	$1.86	45.54
CryoLife	$276.22 million	2.94	$1.72 million	$0.31	67.32

Edwards Lifesciences has higher revenue and earnings than CryoLife. Edwards Lifesciences is trading at a lower price-to-earnings ratio than CryoLife, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Edwards Lifesciences and CryoLife, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edwards Lifesciences	2	5	13	0	2.55
CryoLife	0	1	4	0	2.80

Edwards Lifesciences presently has a consensus price target of $87.7222, indicating a potential upside of 3.57%. CryoLife has a consensus price target of $27.25, indicating a potential upside of 30.57%. Given CryoLife's stronger consensus rating and higher possible upside, analysts plainly believe CryoLife is more favorable than Edwards Lifesciences.

Summary

Edwards Lifesciences beats CryoLife on 10 of the 14 factors compared between the two stocks.